Ciprofloxacin is a new fluorinated quinolone antibiotic with high activity against a wide spectrum of gram-positive and gram-negative bacteria, including methicillin-resistant Staphylococcus aureus, Enterobacteriaceae, and Pseudomonas aeruginosa. Clinical trials using the oral preparation of ciprofloxacin have demonstrated its effectiveness in a wide variety of infections. In addition, extensive clinical trials with the intravenous preparation are underway.
In vitro and in vivo studies with ciprofloxacin have reported the incidence of resistant organisms to be very low. In addition, the incidence of ciprofloxacin-related side effects throughout its clinical trials has been minimal. Most reports of side effects have been related to the gastrointestinal tract, such as nausea or vomiting. The incidence of adverse experiences in worldwide clinical trials has been reported to be approximately 6.4 percent.
ReevesDSBywaterMJHoltHAWhiteLO.In-vitro Studies with ciprofloxacin, a new 4 quinolone compound.J Antimicrob Chemother1984; 13: 333–46.
2.
ChinNNeuHC.Ciprofloxacin, a quinolone carboxylic acid compound active against aerobic and anaerobic bacteria.Antimicrob Agents Chemother1984; 25: 319–26.
3.
EliopoulosGMGardellaAMoelleringRC.In vitro activity of ciprofloxacin, a new carboxyquinolone antimicrobial agent.Antimicrob Agents Chemother1984; 25: 331–5.
4.
RudinJENordenCWShinnersEM.In vitro activity of ciprofloxacin against aerobic gram-negative bacteria.Antimicrob Agents Chemother1984; 26: 597–8.
5.
WattBBrownFV.Is ciprofloxacin active against clinically important anaerobes?J Antimicrob Chemother1986; 17: 605–13.
6.
WolfsonJSHooperDC.The fluoroquinolones: structure, mechanisms of action and resistance, and spectra of activity in vitro.Antimicrob Agents Chemother1985; 28: 581–6.
7.
GordinFMHackbarthCJScottKGSandeMA.Activities of pefloxacin and ciprofloxacin in experimentally induced pseudomonas pneumonia in neutropenic guinea pigs.Antimicrob Agents Chemother1985; 27: 452–4.
8.
BarryALJonesRN.Cross-resistance among cinoxacin, ciprofloxacin, DJ-6783, enoxacin, nalidixic acid, norfloxacin and oxolinic acid after in vitro selection of resistant populations.Antimicrob Agents Chemother1984; 25: 775–7.
9.
TraubWH.Incomplete cross-resistance of nalidixic and pepemidic acid-resistant variants of Serratia marcescens against ciprofloxacin, enoxacin and norfloxacin.Chemotherapy1985; 31: 34–9.
10.
BorobioMVPereaEJ.Effect of inoculum, pH, and medium on the activity of ciprofloxacin against anaerobic bacteria.Antimicrob Agents Chemother1984; 25: 342–3.
11.
ForsgrenA.Comparative in vitro activity of three new quinolone antibiotics against recent clinical isolates.Scand J Infect Dis1985; 17: 91–4.
12.
AldridgeKEJanneyASandersCV.Comparison of the activities of coumermycin, ciprofloxacin, teicoplanin, and other non-β-lactam antibiotics against clinical isolates of methicillin-resistant Staphylococcus aureus from various geographical locations.Antimicrob Agents Chemother1985; 28: 634–8.
13.
SmithSMEngRHBermanE.The effect of ciprofloxacin on methicillin-resistant Staphylococcus aureus.J Antimicrob Chemother1986; 17: 287–95.
14.
ZeilerHJ.Evaluation of the in vitro bacterial action of ciprofloxacin on cells of Escherichia coli in the logarithmic and stationary phases of growth.Antimicrob Agents Chemother1985; 28: 524–7.
15.
ChalkleyLJKoornhofHJ.Antimicrobial activity of ciprofloxacin against Pseudomonas aeruginosa, Escherichia coli, and Staphylococcus aureus determined by killing curve method: antibiotic comparisons and synergistic interactions.Antimicrob Agents Chemother1985; 28: 331–42.
16.
MuytjensHLRos-VanDERepeJVeldhuizenG.Comparative activities of ciprofloxacin (Bay 0 9867), norfloxacin, pipemidic acid, and nalidixic acid.Antimicrob Agents Chemother1983; 24: 302–4.
17.
KelleySGBertramMAYoungLS.Activity of ciprofloxacin against resistant clinical isolates.J Antimicrob Chemother1986; 17: 281–6.
18.
BasseyCMBaltchALSmithRP.Comparative antimicrobial activity of enoxacin, ciprofloxacin, amifloxacin, norfloxacin, and ofloxacin against 177 bacterial isolates.J Antimicrob Chemother1986; 17: 623–8.
19.
KingAShannonKPhillipsI.The in-vitro activity of ciprofloxacin compared with that of norfloxacin and nalidixic acid.J Antimicrob Chemother1984; 13: 325–31.
20.
HawkeyPMHawkeyCA.Comparative in-vitro activity of quinolone carboxylic acids against Proteae.J Antimicrob Chemother1984; 14: 484–9.
21.
HartCAHowSJHobsonD.Activity of ciprofloxacin against genital tract pathogens.Br J Vener Dis1984; 60: 316–8.
22.
HowSJHobsonDHartCAWebsterRE.An in-vitro investigation of synergy and antagonism between antimicrobials against Chlamydia trachomatis.J Antimicrob Chemother1985; 15: 535–8.
23.
SmithSMEngRH.Activity of ciprofloxacin against methicillin-resistant Staphylococcus aureus.Antimicrob Agents Chemother1985; 27: 688–91.
24.
SmithSM.In vitro comparison of A-56619, A56620, amifloxacin, ciprofloxacin, enoxacin, norfloxacin, and ofloxacin against methicillin-resistant Staphylococcus aureus.Antimicrob Agents Chemother1986; 29: 325–6.
25.
ShrireLSaundersJTraynorHJKoornhofHJ.A laboratory assessment of ciprofloxacin and comparable antimicrobial agents.Eur J Clin Microbiol1984; 3: 328–32.
26.
SutterVLKwokYYBulkaczJ.Comparative activity of ciprofloxacin against anaerobic bacteria.Antimicrob Agents Chemother1985; 27: 427–8.
27.
PravhalaRABhavaniRMarshallRMBansalMBThadepalliH.In vitro susceptibility of anaerobic bacteria to ciprofloxacin (Bay 09867).Antimicrob Agents Chemother1984; 26: 785–6.
28.
FliegelmanRMPetrakRMGoodmanLJSegretiJTrenholmeMKaplanRL.Comparative in vitro activities of twelve antimicrobial agents against Campylobacter species.Antimicrob Agents Chemother1985; 27: 429–30.
29.
OverbeekBPRozenberg-ArskaMVerhoefJ.Interaction between ciprofloxacin and tobramycin or azlocillin against multi-resistant strains of Acinetobacter anitratum in vitro (letter).Eur J Clin Microbiol1986; 4: 140–1.
30.
HallerI.Comprehensive evaluation of ciprofloxacin-aminoglycoside combinations against Enterobacteriaceae and Pseudo-monas aeruginosa strains.Antimicrob Agents Chemother1985; 28: 663–6.
31.
CrumpBWiseRDentJ.Pharmacokinetics and tissue penetration of ciprofloxacin.Antimicrob Agents Chemother1983; 24: 784–6.
32.
GonzalezMAUribeFMorsenSDMultiple-dose pharmacokinetics and safety of ciprofloxacin in normal volunteers.Antimicrob Agents Chemother1984; 26: 741–4.
33.
DavisRLKoupJRWilliams-WarrenJ, Pharmacokinetics of three oral formulations of ciprofloxacin.Antimicrob Agents Chemother1985; 28: 74–7.
34.
TartaglioneTARaffalovichACPoymerWJPharmacokinetics and tolerance of ciprofloxacin after sequential increasing oral doses.Antimicrob Agents Chemother1986; 29: 62–6.
35.
BornerKHoffkenGLockHPharmacokinetics of ciprofloxacin in healthy volunteers after oral and intravenous administration.Eur J Clin Microbiol1986; 5: 179–86.
36.
DrusanoGLPlaisanceKIForrestAStandifordHC.Dose range study and constant infusion evaluation of ciprofloxacin.Antimicrob Agents Chemother1986; 30: 440–3.
37.
WiseRLockleyRMWebberlyMDentJ.Pharmacokinetics of intravenous administered ciprofloxacin.Antimicrob Agents Chemother1984; 26: 208–10.
38.
HoffkenGLodeHPrenzingCPharmacokinetics of ciprofloxacin after oral and parenteral administration.Antimicrob Agents Chemother1985; 27: 375–9.
39.
DrusanoGLStandifordHCPlaisanceKAbsolute oral bioavailability of ciprofloxacin.Antimicrob Agents Chemother1986; 30: 444–6.
40.
LedergerberBBettexJDJoosBEffect of standard breakfast on drug absorption and multiple-dose pharmacokinetics of ciprofloxacin.Antimicrob Agents Chemother1985; 27: 350–2.
41.
HoffkenGBornerKGlatzelPDReduced enteral absorption of ciprofloxacin in the presence of antacids (letter).Eur J Clin Microbiol1985: 4:345.
42.
GonzalezMAMoranchelAHDuranSMultiple-dose pharmacokinetics of ciprofloxacin administered intravenously to normal volunteers.Antimicrob Agents Chemother1985; 28: 235–9.
43.
DalhoffAErikenbergHV.Tissue distribution of ciprofloxacin following oral and intravenous administration.Infection1985; 13: 78–81.
44.
FongIWLedbetterWHVandenbrouckeACCiprofloxacin concentrations in bone and muscle after oral dosing.Antimicrob Agents Chemother1986; 29: 405–8.
45.
LebelMValleeFBergeronM.Tissue penetration of ciprofloxacin after single and multiple doses.Antimicrob Agents Chemother1986; 29: 501–5.
46.
BoeremaJBJDalhoffADebruyneFMJ.Ciprofloxacin distribution in prostatic tissue and fluid after oral administration.Chemotherapy1985; 31: 13–8.
47.
BrogardTMJehlFMonteilHComparison of high-pressure liquid chromatography and microbiological assay for the determination of biliary elimination of ciprofloxacin in humans.Antimicrob Agents Chemother1985; 28: 311–4.
48.
SegevSRubinsteinEShickJRabinovitchODolitskyM.Penetration of ciprofloxacin into female pelvic tissues.Eur J Clin Microbiol1986; 5: 207–9.
49.
LockleyMRWaldronRWiseRDonovanIA.Intraperitoneal penetration of ciprofloxacin.Eur J Clin Microbiol1986; 5: 209–10.
50.
Bergogne-BerezinEBerthelotGEvenPSteinMReynaudP.Penetration of ciprofloxacin into bronchial secretions.Eur J Clin Microbiol1986; 5: 197–200.
51.
WolffMBoutronLDecazesJClairBPangonBVochonF.Diffusion of ciprofloxacin into the CSF of patients with purulent meningitis (abstract). Program and abstracts of the 26th Interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans, 1986: 184.
52.
WigenderWBeermannDFousterDFMechanism of renal excretion of ciprofloxacin (Bay 09867) a new quinolone carboxylic acid derivative in humans (abstract). Program and abstracts of the 4th Mediterranean Congress of Chemotherapy. Rhodos, Greece, October 1984: no. 621.
53.
BoelaertJValkeVSchurgersMThe pharmacokinetics of ciprofloxacin in patients with impaired renal function.J Antimicrob Chemother1985; 16: 87–93.
54.
ShalitIGreenwoodRMarksMPedersonJFrederickD.Pharmacokinetics of single-dose oral ciprofloxacin in patients undergoing chronic ambulatory peritoneal dialysis.Antimicrob Agents Chemother1986; 30: 152–6.
55.
LebelMBarbeauGBergeronMGRoyDValleeF.Pharmacokinetics of ciprofloxacin in elderly subjects.Pharmacotherapy1986; 6: 87–91.
56.
ArcieriGAugustRBeckerNClinical experience with ciprofloxacin in the U. S. A.Eur J Clin Microbiol1986; 5: 220–5.
57.
GiamarellouHGalanakisNDendrionsCEvaluation of ciprofloxacin in the treatment of Pseudomonas aeruginosa infections.Eur J Clin Microbiol1986; 5: 232–5.
58.
MehtarSDraboYJBlakemorePH.Ciprofloxacin in the treatment of infections caused by gentamicin-resistant gram-negative bacteria.Eur J Clin Microbiol1986; 5: 248–51.
59.
Van PoppelHWeggeMDammekensHChyskyV.Ciprofloxacin in the treatment of urinary tract infection in patients with multiple sclerosis.Eur J Clin Microbiol1986; 5: 251–3.
60.
LooPSRidgwayGLOrielJD.Single dose ciprofloxacin for treating gonococcal infections in men.Genitourin Med1985; 61: 302–5.
61.
Tegelberg-StassenMJAMVan Der HoekJDMooiL, Treatment of uncomplicated gonococcal urethritis in men with two dosages of ciprofloxacin.Eur J Clin Microbiol1986; 5: 244–6.
62.
ErnstJASyERColon-LuccaH, Ciprofloxacin in the treatment of pneumonia.Antimicrob Agents Chemother1986; 29: 1088–9.
63.
DaviesBIMaesenFPVBaurC.Ciprofloxacin in the treatment of acute exacerbations of chronic bronchitis.Eur J Clin Microbiol1986; 5: 226–31.
64.
SmithMJHodsonMFBattenJC.Ciprofloxacin in cystic fibrosis (letter).Lancet1986; 1: 1103.
65.
ScullyBENeuHCParryMFMandellW.Oral ciprofloxacin therapy of infections due to Pseudomonas aeruginosa.Lancet1986; 1: 819–22.
66.
SandersCCSandersWEGoeringRVWernerV.Selection of multiple antibiotic resistance by quinolones, betalactams, and aminoglycosides with special reference to cross-resistance between unrelated drug classes.Antimicrob Agents Chemother1984; 26: 797–801.
67.
RamirezCABranJLMejiaCRGarciaJF.Open prospective study of the clinical efficacy of ciprofloxacin.Antimicrob Agents Chemother1985; 28: 128–32.
68.
BallA.Overview of clinical experience with ciprofloxacin.Eur J Clin Microbiol1986; 5: 214–9.
69.
MillarMRBransby-ZacharyMATompkinsDSHawkeyPMGibsonRM.Ciprofloxacin for Pseudomonas aeruginosa meningitis (letter).Lancet1986; 1: 1325.
